Intellus Advisors LLC Invests $174,000 in MiMedx Group, Inc. (NASDAQ:MDXG)

Intellus Advisors LLC bought a new position in MiMedx Group, Inc. (NASDAQ:MDXG) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 18,100 shares of the company’s stock, valued at approximately $174,000.

Several other hedge funds also recently made changes to their positions in MDXG. IMG Wealth Management Inc. acquired a new stake in shares of MiMedx Group in the 4th quarter worth $28,000. Van ECK Associates Corp acquired a new stake in shares of MiMedx Group in the fourth quarter valued at about $40,000. Point72 DIFC Ltd lifted its stake in shares of MiMedx Group by 127.6% in the third quarter. Point72 DIFC Ltd now owns 7,626 shares of the company’s stock valued at $45,000 after purchasing an additional 4,275 shares during the period. Orion Capital Management LLC lifted its stake in shares of MiMedx Group by 46.3% in the third quarter. Orion Capital Management LLC now owns 11,700 shares of the company’s stock valued at $69,000 after purchasing an additional 3,700 shares during the period. Finally, SkyView Investment Advisors LLC lifted its stake in shares of MiMedx Group by 30.0% in the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the company’s stock valued at $77,000 after purchasing an additional 3,000 shares during the period. Institutional investors and hedge funds own 79.15% of the company’s stock.

Insiders Place Their Bets

In other news, CAO William Frank Iv Hulse sold 81,446 shares of MiMedx Group stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $7.80, for a total transaction of $635,278.80. Following the completion of the sale, the chief accounting officer now directly owns 494,774 shares in the company, valued at $3,859,237.20. The trade was a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Kimberly Maersk-Moller sold 4,106 shares of MiMedx Group stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $32,396.34. Following the sale, the insider now owns 310,836 shares of the company’s stock, valued at approximately $2,452,496.04. This trade represents a 1.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 144,018 shares of company stock worth $1,130,312. Insiders own 1.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 price objective on shares of MiMedx Group in a research note on Thursday, February 27th.

MiMedx Group Stock Down 0.4 %

Shares of NASDAQ MDXG opened at $7.94 on Friday. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. MiMedx Group, Inc. has a 52 week low of $5.47 and a 52 week high of $10.14. The firm has a 50-day moving average price of $8.37 and a 200 day moving average price of $7.86. The stock has a market capitalization of $1.17 billion, a price-to-earnings ratio of 14.44 and a beta of 1.97.

MiMedx Group (NASDAQ:MDXG) last announced its earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.07. The company had revenue of $92.91 million during the quarter, compared to analysts’ expectations of $89.42 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. Equities research analysts anticipate that MiMedx Group, Inc. will post 0.3 EPS for the current fiscal year.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.